The first international clinical ophthalmological trial concerning treatment of neurotrophic keratitis
Phase I of the clinical trial on the use of recombinant human Nerve Growth Factor
The first international clinical ophthalmological trial concerning treatment of neurotrophic keratitis
Phase I of the clinical trial on the use of recombinant human Nerve Growth Factor
Press conference by the Dompè Group to announce that it has initiated a Phase I Clinical trial on the use of recombinant human Nerve Growth Factor (rhNGF). The first results carried out by the Department of Ophthalmology at Campus Biomedico in Rome, have given the first encouraging results now awaiting the outcome of the multicentric trial just underway.
Press conference by the Dompè Group to announce that it has initiated a Phase I Clinical trial on the use of recombinant human Nerve Growth Factor (rhNGF). The first results carried out by the Department of Ophthalmology at Campus Biomedico in Rome, have given the first encouraging results now awaiting the outcome of the multicentric trial just underway.
videos
Introduction - Eugenio Aringhieri MD - Dompè
Neurotrophic Keratitis
Prof. Stefano Bonini
Specifications of the NGF recombinant human nerve growth factor
Prof. Stefano Bonini
The contribution of industry - Eugenio Aringhieri C.E.O Dompè Group
it
Questions & answers - 1st part
it
Questions & answers - 2nd part
it
Questions & answers - 3rd part
it
